Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data 'Impossible' FDA adcomm ends in favor of Stealth’s ultra-rare disease med Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4 Sanofi flunks midphase multiple sclerosis study, dealing another blow to Denali pact After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap Chutes & Ladders—Lilly goes all-in on AI with new exec position | 